Harnessing molecular vulnerabilities to promote an antitumor immune microenvironment (C02+)

• Subject Area: Cell Biology ; Hematology, Oncology ; Immunology
• Term: from 2019 to 2023
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 413326622

In the project G. Herter-Sprie and C. Reinhardt will employ a next generation genetically engineered mouse model to analyze the role of genomic instability on SCLC immunogenicity and thereby immune surveillance, identify whether radiation and chemotherapy influence the sensitivity towards immunological modulation, and characterize the anti-tumor efficacy of PD-1:PD-L1-blocking antibodies, upon prior regulatory T cells (TReg) repression. Ultimately, the findings from this project will help clinicians to design informed patient-tailored clinical studies.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1399: Mechanisms of drug sensitivity and resistance in small cell lung cancer
• Applicant Institution: Universität zu Köln
• Project Heads: Dr. Grit Sophie Herter-Sprie; Professor Dr. Christian Reinhardt